Press release
Cancer Tyrosine Kinase Inhibitors Market Cancer Tyrosine Kinase Clinical Pipeline Report 2020
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990Report Table of Contents
1. The Journey: Genesis to Present of Tyrosine Kinase Inhibitors
2. Tyrosine Kinase: An Overview
3. Tyrosine Kinases Inhibitors: Promising Tools for Targeted Cancer Therapies
4. Types of Tyrosine Kinase Receptors
4.1 Epidermal Growth Factor Receptor
4.1.1 Types of Epidermal Growth Factor Receptor
4.1.2 Epidermal Growth Factor Receptor & Ligands
4.1.3 Epidermal Growth Factor Receptor & Cancers
4.2 Platelet-Derived Growth Factor Receptor (PDGFR)
4.2.1 Types of Platelet-Derived Growth Factor Receptor
4.2.2 Platelet-Derived Growth Factor Receptor & Ligands
4.2.3 Platelet-Derived Growth Factor Receptor & Cancer
4.3 Insulin-Like Growth Factor 1 Receptor (IGF-1R)
4.3.1 Insulin-Like Growth Factor 1 Receptor & its Ligands
4.3.2 Insulin-Like Growth Factor 1 Receptor & its role in Cancer
5. Signaling Pathway of Receptor Tyrosine Kinase
5.1 PI3K/Akt Pathway
5.2 Ras/Raf/ERK1/2 Pathway
5.3 The JAK/STAT Pathway
6. Advantage of Tyrosine Kinase Inhibitors for Treatment of Cancer
7. BCR-ABL Tyrosine Kinase Inhibitors
7.1 Imatinib
7.2 Nilotinib
7.3 Dasatinib
7.4 Ponatinib
7.5 Bosutinib
8. Epidermal Growth Factor Receptor Kinase Inhibitors Tyrosine
8.1 Gefitinib
8.2 Erlotinib
8. 3 Lapatinib
8.4 Icotinib
8.5 Canertinib
8.6 Afatinib
8.7 Neratinib
8.8 Poziotinib
9. Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitors
9.1 Sunitinib
9.2 Sorafenib
9.3 Vandetanib
9.4 Pazopanib
9.5 Axitinib
9.6 Cediranib
10. Applications of Tyrosine Kinase Inhibitor in Cancer Therapy
10.1 Role of Tyrosine Kinase Inhibitors in the First-Line Treatment of Advanced Non-Small Cell Lung Cancer
10.2 Mitigation of Chronic Myeloid Leukaemia
10.3 Role of tyrosine Kinase Inhibitors in Combating Colorectal Cancer
10.4 Gastrointestinal Cancer & Tyrosine Kinase Inhibitor
10.5 Tyrosine Kinase Inhibitor in Breast Cancer
11. Global Tyrosine Kinase Inhibitors Market Overview
11.1 Current Market Scenario
11.2 Cancer Tyrosine Kinase Inhibitors Pipeline Overview
12. Global Tyrosine Kinase Inhibitor Market Dynamics
12.1 Favorable Driving Factors
12.1.1 Research & Development
12.1.2 Strong Clinical Pipeline
12.1.3 Increasing Disease Incidences
12.1.4 Unmet Requirement of Completely Curative Agents
12.1.5 Advancement in Manufacturing Capabilities of the Biopharmaceutical Companies
12.2 Challenges Countered by Tyrosine Kinase Inhibitor Market
12.2.1 Strict Regulatory Guidelines for Approval of Prospective Drug
12.2.2 Long Phase of Research & Development
12.2.3 Funding of Clinical Trials
12.2.4 Highly Competitive Market
13. Global Tyrosine Kinase Inhibitor Market Future Prospects
14. Global Cancer Tyrosine Kinase Inhibitors Clinical Pipeline by Company, Indication & Phase
14.1 Unknown
14.2 Research
14.3 Preclinical
14.4 Clinical
14.5 Phase-I
14.6 Phase-I/II
14.7 Phase-II
14.8 Phase-II/III
14.9 Phase-III
14.10 Preregistration
14.11 Registered
15. Marketed Cancer Tyrosine Kinase Inhibitors Clinical Insight by Brand Name, Company & Indication
15.1 Blood Cancer
15.1.1 Ibrutinib (Imbruvica)
15.1.2 Ponatinib (Iclusig)
15.1.3 Dasatinib (Tasigna)
15.1.4 Nilotinib (Tasigna)
15.1.5 Bosutinib (Bosulif)
15.1.6 Radotinib (Supect)
15.2 Breast Cancer
15.2.1 Trastuzumab Subcutaneous (Herceptin SC)
15.2.2 Pertuzumab (Omnitarg & Perjeta)
15.2.3 Lapatinib (Tykerb & Tyverb)
15.2.4 Trastuzumab Biosimilar (CANMAb & Hertraz)
15.2.5 Trastuzumab Biosimilar (Vivitra)
15.3 Gastric Cancer
15.3.1 Apatinib
15.4 Non-small cell lung cancer
15.4.1 Afatinib (Gilotrif, Giotrif & Tomtovok)
15.4.2 Nintedanib (Ofev & Vargatef)
15.4.3 Ceritinib (Zykadia)
15.4.4 Crizotinib (Xalkori)
15.4.5 Icotinib (Conmana)
15.4.6 Gefitinib (Iressa)
15.4.7 Alectinib (Alecensa)
15.5 Renal Cancer
15.5.1 Axitinib (Inlyta)
15.6 Thyroid Cancer
15.6.1 Vandetanib (Caprelsa, Zactima & Zictifa)
15.7 Multiple
15.7.1 Sunitinib (Sutent)
15.7.2 Lenvatinib (Lenvima)
15.7.3 Regorafenib (Stivarga)
15.7.4 Imatinib (Gleevec, Glivec & Ruvise)
15.7.5 Trastuzumab (Herceptin)
15.7.6 Erlotinib (Tarceva)
15.7.7 Ramucirumab (Cyramza)
15.7.8 Cabozantinib (COMETRIQ, Cabometyx & Cometriq)
15.7.9 Nimotuzumab (BIOMAb EGFR, CIMAher, Cimaher, Taixinsheng, TheraCIM,
Theraloc & VECTHIX)
15.7.10 Sorafenib (Nexavar)
15.7.11 Imatinib (Imatib)
16. Discontinued & Suspended Cancer Tyrosine Kinase Inhibitors Clinical Pipeline by Company & Phase
16.1 No Development Reported
16.2 Discontinued
16.3 Suspended
17. Competitive Landscape
17.1 AB Science
17.2 Advenchen Laboratories
17.3 Array BioPharma
17.4 ARIAD Pharmaceuticals
17.5 Astellas Pharma (OSI Pharmaceuticals)
17.6 AstraZeneca
17.7 Bayer HealthCare
17.8 Biocad
17.9 Biocon
17.10 Boehringer Ingelheim
17.11 Bristol-Myers Squibb
17.12 Celera Genomics Group
17.13 Celgene Corporation (Avila Therapeutics)
17.14 Celltrion
17.15 Chugai Pharmaceutical
17.16 Cytopia Research
17.17 Daiichi Sankyo (Ambit Biosciences Corporation)
17.18 Dyax
17.19 Eisai Co Ltd
17.20 Exelixis
17.21 GlaxoSmithKline
17.22 Hanmi Pharmaceutical
17.23 Novartis
17.24 Onyx Pharmaceuticals
17.25 Pfizer
17.26 Plexxikon
17.27 Reliance Life Sciences
17.28 Roche
17.29 Shire
17.30 Synthon
17.31 Wyeth
17.32 Xcovery
17.33 Zydus Cadila
Download Report: https://www.kuickresearch.com/report-Global-Cancer-Tyrosine-Kinase-Inhibitors-Market-&-Clinical-Pipeline-Outlook-2020.php
Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.
Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
Avanta Business Center 4th Floor,
Statesman House Barakhamba Road,
Connaught Place New Delhi – 110 001, India
+91-11-47067990
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Cancer Tyrosine Kinase Inhibitors Market Cancer Tyrosine Kinase Clinical Pipeline Report 2020 here
News-ID: 618855 • Views: …
More Releases from Kuick Resarch

Targeted Alpha Therapy Market
Global Targeted Alpha Therapy Market Size, Drugs Approval, Proprietary Technologies & Clinical Trials Insight 2028 Report Highlights:
• Global Targeted Alpha Therapy Market Insight By Region
• Approved Targeted Alpha Therapy Dosage & Pricing Insight
• Number Of Targeted Alpha Therapy In Clinical Trials: > 20 Drugs
• Targeted Alpha Therapy Clinical Trials Insight By Company, Country, Indication & Phase
• Marketed Targeted Alpha Therapy Clinical Insight By Company, Country & Indication
• Targeted Alpha Therapy Proprietary Technology Platform Insights By…

Global Cancer Antibody Drug Conjugates Market
Global Cancer Antibody Drug Conjugates Market Size, Drugs Approval, Price, Sales & Clinical Trials Insight 2030 Report Finding & Inclusions:
• Global Cancer Antibody Drug Conjugates Market: 2020 - 2030
• Global Cancer Antibody Drug Conjugates Market Opportunity > US$ 50 Billion By 2030
• Approved Cancer Antibody Drug Conjugates: 16 Drugs
• Approved Cancer Antibody Drug Conjugates Sales Insights, Patent, Dosage and Price Analysis
• Cancer Antibody Drug Conjugates In Clinical Trials: > 500 Drugs
• Cancer Antibody Drug Conjugates Clinical…

Cancer Peptide Drugs Market
Global Peptide Cancer Drug Market Size, Dosage, Drug Price, Sales & Clinical Trials Insight 2030 Report Highlights:
• Global Peptide Cancer Drug Market Insight By Region & Indication
• Global Peptide Cancer Drug Market Opportunity: > US$ 18 Billion
• Approved Peptide Cancer Drugs: > 30 Drugs
• Approved Peptide Cancer Drugs Sales Insights, Patent, Dosage and Price Analysis
• Peptide Cancer Drugs Clinical Trials Insight By Company, Country, Indication and Phase
• Insight On Peptide Cancer Drugs In Clinical Trials: >…

Bispecific Antibody Drug Conjugates Development
The development of bispecific antibody drug conjugates (ADCs) marks a significant advancement in the field of targeted cancer therapy. These innovative molecules combine the specificity of bispecific antibodies with the powerful cytotoxic effects of drug conjugates, creating a new class of therapeutic agents that hold great promise for treating complex and resistant cancers. The process of developing these ADCs involves intricate design, engineering, and testing to ensure their safety, efficacy,…
More Releases for Tyrosine
Global Tyrosine Supplements Market: A Comprehensive Overview
The global tyrosine supplements market was valued at approximately USD 1.2 billion in 2023 and is projected to reach around USD 2.8 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 10.9% from 2024 to 2030.
Global Tyrosine Supplements Market Overview
The global tyrosine supplements market is experiencing significant growth, driven by increasing consumer awareness of its cognitive and mood-enhancing benefits. Tyrosine, an amino acid, is widely…
Bruton Tyrosine Kinase (BTK) Inhibitors Market
Introduction
Bruton Tyrosine Kinase (BTK) inhibitors represent a critical class of medications in the treatment of various cancers, primarily blood-related malignancies. BTK is an enzyme crucial in the B-cell receptor signaling pathway, essential for B-cell development and function. This signaling pathway plays a central role in many types of blood cancers such as chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). By inhibiting BTK, these drugs effectively prevent the proliferation…
Global Tyrosine Market 2015-2025 | Growing Opportunities and Trends in Tyrosine …
The Market Research Store has added the latest report on the Global Tyrosine Market which includes the historical data from 2015 to 2019 and has also precisely forecasted data from 2020 to 2025. The global Tyrosine market anticipates to showcase market value in terms of USD Million during the forecast period 2020 to 2025. According the research analyst the market will witness a steady growth during the coming years.
Get Sample…
Tyrosine Market Size, Share, Development by 2024
Global Info Research offers a latest published report on Tyrosine Market Analysis and Forecast 2019-2025 delivering key insights and providing a competitive advantage to clients through a detailed report. The report contains 102 pages which highly exhibit on current market analysis scenario, upcoming as well as future opportunities, revenue growth, pricing and profitability.
Click to view the full report TOC, figure and tables:
https://www.globalinforesearch.com/global-tyrosine-market_p130094.html
Scope of the Report:
The worldwide market for Tyrosine is…
Glycyl Tyrosine Market SWOT Analysis 2018-2023
Future Market Reports on Global Glycyl Tyrosine 2018 Research Report presents a professional and complete analysis of Global Glycyl Tyrosine Market on the current market situation. The Global Glycyl Tyrosine Market 2018 report includes Glycyl Tyrosine market Revenue, market Share, Glycyl Tyrosine industry volume, market Trends, Growth aspects. It analyses the important factors of the Glycyl Tyrosine market based on present industry situations, Glycyl Tyrosine market demands, business strategies utilized…
Tyrosine Kinase Inhibitors Market & Pipeline Insight 2015
Tyrosine kinase is a sub class of Protein Kinases family of enzyme responsible for phosphorylation.It has been found that mutation or other anomaly in these enzymes causes uncontrolled cell division leading to cancer. Because of their direct involvement in cell division they are used in cancer treatment by using kinase inhibitors to prevent unregulated cellular proliferation. Epidermal Growth Factor Receptor Family (EFGR) are present on the cell surface and anomalies…